Navigation Links
Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Date:9/23/2008

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of heart failure, at the 12th Annual Scientific Meeting of the Heart Failure Association of America at the Metro Toronto Convention Centre, Toronto, Ontario, Canada on September 22, 2008.

The Phase 1 trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 26 healthy volunteers who received the medication or placebo subcutaneously. The objective of the trial was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered PL-3994 in healthy male subjects.

Dosing concluded with the successful achievement of the primary endpoint of the study, a prespecified reduction in systemic blood pressure. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP, and increases in urine volume and sodium excretion. There were no serious or severe adverse events.

The data set presented in poster format is available for viewing on Palatin's website at http://www.palatin.com.

Palatin completed a positive Phase 2a clinical study with PL-3994 last month in 21 volunteers with controlled hypertension who received the medication or placebo subcutaneously. The results of the study demonstrated that PL-3994 can be given safely to patients taking antihypertensive medications commonly administered to heart failure and hypertension patients.

"We are very excited with the results and progress of o
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology, announced ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... you to join us for this Company update," ... on our commercial launch of the exVive3D Liver, ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today announced ... covering the stimulator used in the Urgent® PC ... an office-based, non-surgical system, used to treat overactive ...
... LCAV ), a leading provider of laser vision correction ... management will present at the Lazard Capital Markets 8th Annual ... Eastern time. The conference is being held at the Pierre ... of the presentation will be available at the Investor Relations ...
Cached Medicine Technology:Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator 2
(Date:2/28/2015)... NV (PRWEB) February 28, 2015 My Shiney ... be sending a team to Las Vegas, Nevada for the ... Week is one of the leading consumer-goods tradeshows and My ... at this year’s event. My Shiney Hiney can be found ... fresh, modern design for the at-home personal hygiene brush and ...
(Date:2/27/2015)... February 27, 2015 Wireless Analytics, ... services, and one of the founders of ... for Bell Mobility within their CLEAN Platform™ (Communications ... Wireless Analytics’ newly developed Bell Mobility Data ... the Canadian wireless carrier’s business customers. , Wireless ...
(Date:2/27/2015)... February 27, 2015 Just a little ... for those suffering from Sjögren’s Syndrome after a new ... researchers at the University of Buffalo and Immco Diagnostics, ... research was to develop a new diagnostic test ... presence of new autoantibodies. Researchers aimed to develop a ...
(Date:2/27/2015)... Bethesda, MD (PRWEB) February 27, 2015 ... Foundation (Meso Foundation) and the National Cancer Institute ... Malignant Mesothelioma at the National Institutes of Health ... parts: one part is dedicated to medical professionals ... other is directed to the general public, including ...
(Date:2/27/2015)... February 27, 2015 Altec Products, Inc., ... their Sage ERP Document Management Partner of the Year. ... Sage CRM and other complimentary solutions for their customers ... side-by-side for many years to provide clients with paperless ... , “We are thrilled to recognize ADSS Global ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2
... drug and vaccine research is booming. According to a report ... George Institute for International Health, 16 new malaria vaccine candidates ... about to reach the market; and by 2011 we will ... , However, this unprecedented level of malaria R&D activity ...
... Oct. 4 Health information,technology (HIT) is a ... but it must be implemented to interact with ... according to a new report by,BearingPoint, prepared for ... is a nonpartisan independent body based in Washington,but ...
... Outlook Excluding Discrete Tax Items -, LIONVILLE, Penn., Oct. ... provided an update to its full year 2007,guidance. The Company ... its earnings per share guidance at between $2.27 and $2.37 ... in the third quarter a net discrete tax charge of ...
... Approval for Alternate ICG Manufacturing Site, TORONTO, ... a developer of real-time medical imaging systems and ... has received a,sufficient supply of ICG to immediately ... currently the exclusive suppliers of,indocyanine green (ICG) in ...
... to the,November 2006 Rand Corp. study, health care ... billion a year nationally and that 68,percent of ... adopted,tens of millions of newcomers, U.S.-born and foreign-born ... years to the U.S. population.,They will also consume ...
... 4 People who eat out,tend to consume more ... prefer takeout to the kitchen also tend to consume ... body needs to stay healthy. (Photo: http://www.newscom.com/cgi-bin/prnh/20071004/NYTHFNS2 ... said Peggy Fleming, Olympic figure,skating champion and HealthSaver spokesperson. ...
Cached Medicine News:Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 2Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 2Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 4Health News:West Pharmaceutical Services Updates Annual Guidance 2Health News:West Pharmaceutical Services Updates Annual Guidance 3Health News:Novadaq Resumes Normal Business Operations by Securing ICG for SPY 2Health News:Novadaq Resumes Normal Business Operations by Securing ICG for SPY 3Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 4
Performa cemented stem....
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Medicine Products: